#ASCO18. First author: Dr. Tomas Pascual & Senior @prat_aleix Evaluating the ability of this combined biomarker to predict response and survival following anti-HER2 therapy alone in T-refractory HER2+ BC. @hospitalclinic & @idibaps
Now at #ASCO18: HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.